Bardoxolone is the NFR2 activator from Reata, used in BEACON, that BKC, Cityslicker and Tada were all referring to. 

I did a brain dump on this a while back. I also touched on Reata's compounds in this post. Also, bardoxolone in Alport syndrome recently reported positive Phase 3 renal results. The Phase 3 AYAME trial is testing safety and efficacy in diabetic CKD, the closest comparator to BETonMACE. This is a follow up trial after BEACON was stopped early for concerns of increased death.

BDAZ